A cup and a half of leafy green vegetables could go a long way to addressing atherosclerotic vascular diseases (ASVD’s), new research from Edith Cowan University (ECU), the University of Western Australia and the Danish Cancer Institute has found.  

In May 2025, the Journal for ImmunoTherapy of Cancer published a pioneering study entitled “NeoPred: dual-phase CT AI forecasts pathologic response to neoadjuvant chemo-immunotherapy in NSCLC”, led by Professor Jianxing He’s team from the First Affiliated Hospital of Guangzhou Medical University / National Center for Respiratory Medicine.

The study introduces NeoPred, a multimodal artificial intelligence model that combines dual-phase CT scans (pre-treatment and pre-surgery) and clinical features to predict major pathological response (MPR) before surgery in patients undergoing neoadjuvant chemo-immunotherapy for non-small cell lung cancer (NSCLC).

Corresponding Authors: Prof. Jianxing He, Dr. Hengrui Liang Co-First Authors: Dr. Jianqi Zheng, Mr. Zeping Yan, Mr. Runchen Wang Collaborating Institutions: Shanghai Chest Hospital, Liaoning Cancer Hospital, First Affiliated Hospital of Xi’an Jiaotong University

A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene—commonly altered in prostate cancer—drive tumor initiation formation and therapeutic resistance.

The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Promising treatment results for blood cancers, colorectal cancer and brain metastases. Novel insights into early pancreatic cancer cell progression. A new therapeutic target for patients with high blood pressure

NRG Oncology (NRG), a National Cancer Institute (NCI) National Clinical Trials Network (NCTN) group focused on improving outcomes for adults with cancer through multi-center clinical research, recently announced that Tambre Leighn was appointed Committee Chair of the NRG Patient Advocate Committee (PAC) and Dr. Chris Holsinger was appointed Surgical Vice Chair of the NRG Head and Neck Cancer (HNC) Committee.